Buchumschlag

Reprogramming innate immunity to overcome endocrine resistance in estrogen receptor‐positive breast cancer

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Siti Nur Hasyila Muhammad, Maryam Azlan, Agustine Nengsih Fauzi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	International Journal of Cancer
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Exploring Terpenoids as Dual‐Action Agents in Diabetes and Cancer: A Review of Their Anti‐Hyperglycemic, Anti‐Glycolytic Actions, and Combination Therapy Potential
von: Siti Nur Hasyila Muhammad, et al.
Veröffentlicht: (2026)

Trends in breast cancer incidence by estrogen receptor status in the United States , 2004–2020
von: Chenxi Jiang, et al.
Veröffentlicht: (2024)

Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study
von: Layla Andour, et al.
Veröffentlicht: (2025)

Estrogen, estrogen receptor and the tumor microenvironment of NSCLC
von: Mingxin Diao, et al.
Veröffentlicht: (2025)

Terpenoids: Unlocking Their Potential on Cancer Glucose Metabolism
von: Siti Nur Hasyila Muhammad, et al.
Veröffentlicht: (2024)

Asparagine synthetase and G‐protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer
von: Lingeng Lu, et al.
Veröffentlicht: (2024)

Reprogramming SREBP1 ‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention
von: Atieh Hajirahimkhan, et al.
Veröffentlicht: (2025)

Progesterone receptor ( PR ) intra‐tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial
von: Oscar Danielsson, et al.
Veröffentlicht: (2025)

Real‐world progression‐free survival and overall survival in patients with HR + / HER2 − advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study
von: Peter A. Fasching, et al.
Veröffentlicht: (2026)

Long‐term benefit from adjuvant tamoxifen therapy for ER + HER2− breast cancer by PR positivity
von: Anna E. Nordenskjöld, et al.
Veröffentlicht: (2026)

The critical role of discoidin domain receptors in the regulation of anti‐tumor immune responses
von: Sixin Jiang, et al.
Veröffentlicht: (2026)

Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
von: Milena Beierlein, et al.
Veröffentlicht: (2025)

Clinical impact of real‐time androgen receptor alteration monitoring on metastatic castration‐resistant prostate cancer treatment in real‐world settings
von: Regina Stitz, et al.
Veröffentlicht: (2025)

Roles of leukemia inhibitory factor receptor in cancer
von: Wei Ma, et al.
Veröffentlicht: (2024)

Enhancing breast cancer knowledge and clinical breast examination skills among healthcare providers at the polyclinics in Misrata, Libya
von: Muna Abusanuga, et al.
Veröffentlicht: (2026)

Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults
von: Katharina Daugs, et al.
Veröffentlicht: (2025)

Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors
von: Carolyn Brandt, et al.
Veröffentlicht: (2024)

Comparison of iBreastExam with clinical breast examination for early detection of breast cancer in community outreach clinics in Pune, India
von: Smita N. Joshi, et al.
Veröffentlicht: (2025)

Education level and risk of breast cancer by tumor subtype in the EPIC cohort
von: Margherita Pizzato, et al.
Veröffentlicht: (2025)

Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis
von: Yuhan Bao, et al.
Veröffentlicht: (2024)

Age‐related phenotypes in breast cancer: A population‐based study
von: Amalie A. Svanøe, et al.
Veröffentlicht: (2024)

Mammographic density and breast cancer risk among Black American women
von: Etienne X. Holder, et al.
Veröffentlicht: (2024)

Postmarketing adverse events of tamoxifen in male and female patients with breast cancer
von: Chengjie Ke, et al.
Veröffentlicht: (2024)

Clinical efficacy of tumor organoid‐guided cancer therapy for locally advanced unresectable or metastatic breast cancer
von: Ying‐yi Lin, et al.
Veröffentlicht: (2024)

Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry
von: Marc Thill, et al.
Veröffentlicht: (2024)

The role of cytokines in ovarian cancer drug resistance
von: Lu Wang, et al.
Veröffentlicht: (2025)

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients
von: Huizi Wu, et al.
Veröffentlicht: (2024)

Preeclampsia and risk of breast cancer: A longitudinal cohort study of tumor histology
von: Shu Qin Wei, et al.
Veröffentlicht: (2025)

Correction to “Natural resistance to cancer: A window of hope”
Veröffentlicht: (2024)

Trends in the incidence of cancers of the breast and female genital tract in Harare, Zimbabwe 1990–2019
von: Eric Chokunonga, et al.
Veröffentlicht: (2026)

Patient factors and modifications to intended chemotherapy for women with Stages I–IIIA breast cancer
von: Jenna Bhimani, et al.
Veröffentlicht: (2025)

Comparative sequencing study of mismatch repair and homology‐directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan
von: Ying Zheng, et al.
Veröffentlicht: (2024)

Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India
von: Atul Budukh, et al.
Veröffentlicht: (2024)

Metformin and other anti‐diabetic medication use and breast cancer incidence in the Nurses' Health Studies
von: Tengteng Wang, et al.
Veröffentlicht: (2024)

Neuro–astrocytic network in breast cancer brain metastases: Adaptive mechanisms and novel therapeutic targets
von: Tao Huang, et al.
Veröffentlicht: (2025)

Overall and central adiposity and risk of contralateral breast cancer: The California Breast Cancer Survivorship Consortium
von: Esther M. John, et al.
Veröffentlicht: (2025)

Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registry
von: Patrick Marschner, et al.
Veröffentlicht: (2026)

Toll‐like receptor 13‐mediated signaling protects against the development of colon cancer
von: Asma Rafique, et al.
Veröffentlicht: (2024)

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany
von: Min‐Wai Lwin, et al.
Veröffentlicht: (2026)

SAA1‐dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness
von: Ilona Rybinska, et al.
Veröffentlicht: (2024)